Physician profile
Ilhem Remmouche
NPI 1366684854
$4,761.46
in general payments reported to CMS, 2019-2025
29 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.99 · 2021: $17.42 · 2022: $693 · 2023: $911 · 2024: $1,627 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $684.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $671.20 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $654.60 | 2022-2025 | |
| Lilly USA, LLC | $438.95 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $319.30 | 2022-2025 | Freestyle Libre 3, Eterna |
| Bausch Health US, LLC | $294.24 | 2022-2025 | Aplenzin, Wellbutrin |
| Glaxosmithkline, LLC. | $268.73 | 2022-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Sumitomo Pharma America, INC. | $233.31 | 2023-2025 | Gemtesa |
| Amgen INC. | $219.89 | 2022-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $164.98 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $118.14 | 2023-2025 | |
| Astellas Pharma US INC | $117.28 | 2023-2024 | Veozah |
| Janssen Biotech, INC. | $72.80 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $63.62 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.90 | 2023-2025 | Xifaxan, Trulance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $58.63 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $43.97 | 2022-2023 | Eliquis |
| Masimo Corporation | $35.00 | 2019 | |
| Averitas Pharma INC. | $30.35 | 2025 | Qutenza |
| Ucb, INC. | $27.19 | 2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $26.90 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.49 | 2024 | Spravato |
| Kiniksa Pharmaceuticals International, Plc | $21.15 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $20.56 | 2023 | Arcalyst |
| Sunovion Pharmaceuticals INC. | $19.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.89 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $17.71 | 2022 | |
| Vivus LLC | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilhem Remmouche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.